Camillo Porta
卡米洛·波尔塔
MD, PhD
Professor of Medical Oncology; Head, Division of Medical Oncology肿瘤内科教授；肿瘤内科主任
👥Biography 个人简介
Camillo Porta, MD PhD is Professor of Medical Oncology and Head of the Division of Medical Oncology at the University of Bari, Italy. He is one of Europe's foremost experts in systemic therapy for renal cell carcinoma and a longstanding contributor to ESMO RCC clinical practice guidelines. His work encompasses mTOR inhibitor development, sequential targeted therapy strategies, and biomarker-driven treatment selection in advanced kidney cancer.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
mTOR Inhibitor Therapy in Advanced RCC
Conducted pivotal clinical and translational research on temsirolimus and everolimus in advanced RCC, contributing to understanding of mTOR pathway biology and defining optimal patient populations for mTOR inhibitor therapy including poor-risk and non-clear cell histologies.
ESMO RCC Guidelines Long-term Authorship
Served as a co-author on multiple consecutive editions of the ESMO clinical practice guidelines for renal cell carcinoma over more than a decade, providing continuous expert synthesis of emerging trial data into practical European treatment recommendations.
Sequential and Combination Therapy Strategies in RCC
Led and participated in clinical trials examining optimal sequencing of VEGFR TKIs, mTOR inhibitors, and IO agents in advanced RCC, generating evidence that informed clinical decision-making in the rapidly evolving treatment landscape.
Representative Works 代表性著作
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
New England Journal of Medicine (2007)
ARCC phase III trial establishing temsirolimus as the first approved therapy for poor-risk advanced RCC, demonstrating OS benefit over interferon and validating mTOR as a therapeutic target in kidney cancer.
ESMO Clinical Practice Guidelines for Renal Cell Carcinoma: Diagnosis, Treatment and Follow-up
Annals of Oncology (2019)
ESMO guideline for advanced RCC incorporating IO-based combinations alongside TKI monotherapy, providing European oncologists with a comprehensive algorithmic framework for first- and subsequent-line treatment decisions.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Brian I. Rini
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Robert J. Motzer
Memorial Sloan Kettering Cancer Center
Toni K. Choueiri
Dana-Farber Cancer Institute, Harvard Medical School
Sumanta Pal
City of Hope Comprehensive Cancer Center
关注 卡米洛·波尔塔 的研究动态
Follow Camillo Porta's research updates
留下邮箱，当我们发布与 Camillo Porta（University of Bari 'Aldo Moro' / A.O.U. Consorziale Policlinico）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment